Clinical trials: Fungal Infection
Cutaneous T-Cell Lymphoma
Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
This study evaluated the safety and efficacy of LBH589B in adult participants with refractory/resistant Cutaneous T-Cell Lymphoma and prior Histone Deacetylase (HDAC) inhibitor therapy.
- Trial name
- NCT00490776
- Testing
- Panobinostat
- Where
- 18 sites in United States
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Infections, Streptococcal, Streptococcus Pneumoniae Vaccines
Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine
This protocol posting deals with objectives \& outcome measures of the extension phase up to 48-50 months post booster vaccination, to assess long-term antibody persistence in children at around 30, 42 and 66 months of age, who…
- Trial name
- NCT00624819
- Testing
- GSK1024805A, Prevenar, Infanrix hexa
- Where
- 6 sites in Poland
- Volunteers
- 524 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tetanus, Diphtheria
Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age
Currently, there is no 5-component acellular pertussis vaccine licensed for the 5th dose in US children aged 4 to 6 years.This study is aimed at providing evidence of sero-protection, booster response and safety of this…
- Conditions
- Tetanus, Diphtheria, Pertussis
- Trial name
- NCT00467519
- Testing
- Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis), DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)
- Where
- 43 sites in United States, Canada
- Volunteers
- 1,045 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Tetanus
A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred.
- Trial name
- NCT07107932
- Testing
- Siltartoxatug Injection (Brand name: Sintetol®)
- Where
- 4 sites in China
- Volunteers
- 10,000 people
- Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
Pneumococcal Infection
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae.
- Trial name
- NCT07300267
- Testing
- V118C (Stage 1), V118C (Stage 2), PCV20 (Stage 1)
- Where
- 15 sites in United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumonia, Bacterial, Community-Acquired Infections
A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
The purpose of this study is to evaluate the safety and tolerability of doripenem compared to cefepime in children hospitalized with pneumonia.
- Conditions
- Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
- Trial name
- NCT01110421
- Testing
- Cefepime, Doripenem, Amoxicillin/clavulanate potassium
- Where
- 25 sites in United States, Argentina and 8 more
- Volunteers
- 7 people
- Sponsor
- Janssen Research & Development, LLC
Infections, Staphylococcal
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of several formulations of an investigational Staphylococcal vaccine.
- Trial name
- NCT01160172
- Testing
- Staphylococcal investigational vaccine GSK2392103A, Staphylococcal investigational vaccine GSK2392105A, Staphylococcal investigational vaccine GSK2392106A
- Where
- Belgium
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Aspergillosis
An Observational Study of Fungal Biomarkers (MK-0000-089)
The purpose of this study is to evaluate the relationship between fungal biomarker levels during anti-fungal therapy and the success of treatment for fungal infection.
- Trial name
- NCT00854607
- Testing
- No Intervention
- Volunteers
- 116 people
- Sponsor
- Merck Sharp & Dohme LLC
Skin Diseases, Bacterial
A Study to Evaluate the Effects of Tedizolid Phosphate on the Pharmacokinetics and Safety of Midazolam and Rosuvastatin (MK-1986-004)
The purpose of this study is to assess the effect of steady-state tedizolid phosphate on the single-dose pharmacokinetics of midazolam and rosuvastatin in healthy, adult participants.
- Trial name
- NCT02477514
- Testing
- midazolam, rosuvastatin, tedizolid phosphate
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Meningococcal Disease, Meningitis
Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children
This study is part of the post-licensure commitment to evaluate the safety and immunogenicity of Meningo A+C vaccine in healthy Chinese children 2 to 6 years of age.
- Trial name
- NCT01430611
- Testing
- Meningococcal (Groups A and C) Polysaccharide Vaccine
- Where
- 2 sites in China
- Volunteers
- 666 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
The objective of this clinical study is to compare the safety and effectiveness of Valchlor versus HyBryte following 12 weeks of treatment.
- Trial name
- NCT06149247
- Testing
- Hypericin, Mechlorethamine Topical Gel
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Soligenix
Poliomyelitis, Tetanus
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).
This study will evaluate the immunogenicity of the co-administration of different combinations of DTPa, IPV, hepatitis B, Hib and Men C vaccines during the first year of life.
- Conditions
- Poliomyelitis, Tetanus, Acellular Pertussis, Hepatitis B
- Trial name
- NCT00352963
- Testing
- Study vaccines: IH+Hib-MenC/NVC; Control: IH+Meningitec
- Where
- 22 sites in Spain
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Tuberculosis
Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis
Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Hepatic Injury ( ATDH ) in Subjects with Pulmonary Tuberculosis
- Trial name
- NCT02467608
- Testing
- Isoniazid with HUEXC030 and RZE, HRZE
- Where
- 18 sites in Taiwan
- Volunteers
- 557 people
- Sponsor
- Orient Pharma Co., Ltd.
Gram-negative Bacterial Infection
A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)
The purpose of this study is to learn about the safety and effects of ATM-AVI for the possible treatment of infections caused by a type of bacteria called gram-negative bacteria.
- Trial name
- CHERISH (NCT06462235)
- Testing
- Part A: ATM-AVI Single Dose, Cohorts 1-4, Part B: Multiple-dose ATM-AVI, Cohorts 1-4
- Where
- 32 sites in United States, Argentina and 7 more
- Volunteers
- 48 people
- Sponsor
- Pfizer
Multi-drug Resistant Tuberculosis
A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis
The purpose of this study is to provide safety and efficacy data for TMC207 and to demonstrate that TMC207 added to a background regimen (BR) is superior to treatment with the BR plus placebo.
- Trial name
- NCT01600963
- Testing
- Arm A Double-blind Phase: TMC207, Treatment Failure During Double-blind Phase: TMC207, Treatment Failure During Follow-up Phase: TMC207
- Where
- 44 sites in Brazil, Cambodia and 15 more
- Sponsor
- Janssen Infectious Diseases BVBA
Gram-negative Bacterial Infections
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections
The purpose of this study is to evaluate how Aztreonam (ATM) and Avibactam (AVI) are processed in pediatric participants. This study also aims to understand participant safety and effects in pediatric participants.
- Trial name
- NCT05639647
- Testing
- ATM-AVI, BAT
- Where
- 22 sites in United States, China and 6 more
- Volunteers
- 48 people
- Sponsor
- Pfizer
Diarrhea, Gastroenteritis
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
The goal of this clinical trial is to learn how rifaximin 200 mg is processed in the body (pharmacokinetics) in children 6 to 11 years old with acute diarrhea that may be caused by bacteria.
- Conditions
- Diarrhea, Gastroenteritis, Bacterial Infection, Acute Diarrhea
- Trial name
- NCT07285785
- Testing
- Rifaximin 200 mg Tablet, Oral Rehydration Therapy (ORT)
- Where
- 10 sites in United States
- Volunteers
- 54 people
- Sponsor
- Bausch Health Americas, Inc.
Infections, Meningococcal
Combined Study - Phase 3b MenB Long Term Persistence in Adolescents
The purpose/aim of this study is to assess 1) the long-term persistence (4 to 7.5 years after the last dose) of bactericidal activity following primary vaccination with rMenB+OMV NZ in adolescents [who previously participated in…
- Trial name
- NCT02446743
- Testing
- rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)
- Where
- 12 sites in Australia, Canada and 1 more
- Volunteers
- 531 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infection, Bacterial
Evaluation of ATx201 as a Topical Antibiotic Agent
AntibioTx is developping ATx201 as a topical product for treatment of skin infections, including infected atopic dermatitis.
- Trial name
- NCT03009734
- Testing
- ATx201 dermal formulations 2%
- Where
- Austria
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- UNION therapeutics
Tinea Pedis
Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
To assess the efficacy and safety of a combination product S2G6T-1 compared to its monads and vehicle, applied twice daily for 7 days, in the treatment of symptomatic inflammatory interdigital tinea pedis in subjects 12 years of…
- Trial name
- NCT02842021
- Testing
- S2G6T-1, S2G6T-2, S2G6T-3
- Where
- 19 sites in United States
- Volunteers
- 283 people
- Sponsor
- Sol-Gel Technologies, Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.